Asensus Surgical Announces Purchase of Senhance Robotic System by RZD Medicine
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery, today announced Private Healthcare Institution Railway Clinical Hospital RZD Medicine of Rostov-on-Don (RZD Medicine), located in Rostov, Russia, has initiated its Senhance Robotic Surgery program following the purchase of a Senhance Surgical System.
- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery, today announced Private Healthcare Institution Railway Clinical Hospital RZD Medicine of Rostov-on-Don (RZD Medicine), located in Rostov, Russia, has initiated its Senhance Robotic Surgery program following the purchase of a Senhance Surgical System.
- RZD Medicine is home to a high volume, multidisciplinary general surgery department that can leverage Senhance across a wide variety of procedures, said Anthony Fernando, Asensus Surgical President and CEO.
- Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning.
- This press release includes statements relating to the Senhance Surgical System and RZD Medicine initiating a program with the Senhance System.